Auckland City Hospital, Auckland, New Zealand; University of Auckland, Auckland, New Zealand.
Auckland City Hospital, Auckland, New Zealand; University of Auckland, Auckland, New Zealand.
Lancet. 2019 Nov 23;394(10212):1907-1914. doi: 10.1016/S0140-6736(19)32315-3. Epub 2019 Oct 20.
An association between increasing anaesthetic depth and decreased postoperative survival has been shown in observational studies; however, evidence from randomised controlled trials is lacking. Our aim was to compare all-cause 1-year mortality in older patients having major surgery and randomly assigned to light or deep general anaesthesia.
In an international trial, we recruited patients from 73 centres in seven countries who were aged 60 years and older, with significant comorbidity, having surgery with expected duration of more than 2 h, and an anticipated hospital stay of at least 2 days. We randomly assigned patients who had increased risk of complications after major surgery to receive light general anaesthesia (bispectral index [BIS] target 50) or deep general anaesthesia (BIS target 35). Anaesthetists also nominated an appropriate range for mean arterial pressure for each patient during surgery. Patients were randomly assigned in permuted blocks by region immediately before surgery, with the patient and assessors masked to group allocation. The primary outcome was 1-year all-cause mortality. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12612000632897, and is closed to accrual.
Patients were enrolled between Dec 19, 2012, and Dec 12, 2017. Of the 18 026 patients screened as eligible, 6644 were enrolled, randomly assigned to treatment or control, and formed the intention-to-treat population (3316 in the BIS 50 group and 3328 in the BIS 35 group). The median BIS was 47·2 (IQR 43·7 to 50·5) in the BIS 50 group and 38·8 (36·3 to 42·4) in the BIS 35 group. Mean arterial pressure was 3·5 mm Hg (4%) higher (median 84·5 [IQR 78·0 to 91·3] and 81·0 [75·4 to 87·6], respectively) and volatile anaesthetic use was 0·26 minimum alveolar concentration (30%) lower (0·62 [0·52 to 0·73] and 0·88 [0·74 to 1·04], respectively) in the BIS 50 than the BIS 35 group. 1-year mortality was 6·5% (212 patients) in the BIS 50 group and 7·2% (238 patients) in the BIS 35 group (hazard ratio 0·88, 95% CI 0·73 to 1·07, absolute risk reduction 0·8%, 95% CI -0·5 to 2·0). Grade 3 adverse events occurred in 954 (29%) patients in the BIS 50 group and 909 (27%) patients in the BIS 35 group; and grade 4 adverse events in 265 (8%) and 259 (8%) patients, respectively. The most commonly reported adverse events were infections, vascular disorders, cardiac disorders, and neoplasms.
Among patients at increased risk of complications after major surgery, light general anaesthesia was not associated with lower 1-year mortality than deep general anaesthesia. Our trial defines a broad range of anaesthetic depth over which anaesthesia may be safely delivered when titrating volatile anaesthetic concentrations using a processed electroencephalographic monitor.
Health Research Council of New Zealand; National Health and Medical Research Council, Australia; Research Grant Council of Hong Kong; National Institute for Health and Research, UK; and National Institutes of Health, USA.
观察性研究表明,麻醉深度增加与术后生存率降低之间存在关联;然而,随机对照试验的证据尚缺乏。我们的目的是比较接受主要手术的老年患者的全因 1 年死亡率,这些患者被随机分为接受浅麻醉或深麻醉。
在一项国际试验中,我们从 7 个国家的 73 个中心招募了年龄在 60 岁及以上、合并症严重、预计手术时间超过 2 小时、预计住院时间至少 2 天的患者。我们将接受大手术后并发症风险增加的患者随机分配接受浅全身麻醉(脑电双频指数[BIS]目标值 50)或深全身麻醉(BIS 目标值 35)。麻醉师还为每位患者在手术期间指定了平均动脉压的适当范围。患者在手术前立即按区域以区组随机分配,患者和评估者对分组分配均设盲。主要结局是 1 年全因死亡率。该试验在澳大利亚和新西兰临床试验注册中心(ACTRN12612000632897)注册,目前已停止入组。
患者于 2012 年 12 月 19 日至 2017 年 12 月 12 日之间进行筛选,符合条件的 18646 名患者中,有 6644 名患者被纳入研究并随机分配至治疗组或对照组,形成意向治疗人群(BIS 50 组 3316 例,BIS 35 组 3328 例)。BIS 50 组的中位数 BIS 为 47.2(IQR 43.7 至 50.5),BIS 35 组为 38.8(36.3 至 42.4)。平均动脉压高 3.5mmHg(4%)(中位数分别为 84.5[IQR 78.0 至 91.3]和 81.0[75.4 至 87.6]),挥发性麻醉药使用量低 0.26 最低肺泡浓度(30%)(中位数分别为 0.62[0.52 至 0.73]和 0.88[0.74 至 1.04]),BIS 50 组比 BIS 35 组。BIS 50 组的 1 年死亡率为 6.5%(212 例),BIS 35 组为 7.2%(238 例)(风险比 0.88,95%CI 0.73 至 1.07,绝对风险降低 0.8%,95%CI -0.5 至 2.0)。BIS 50 组 954 例(29%)患者发生 3 级不良事件,BIS 35 组 909 例(27%)患者发生 3 级不良事件;BIS 50 组 265 例(8%)和 BIS 35 组 259 例(8%)患者发生 4 级不良事件。最常见的不良事件是感染、血管疾病、心脏疾病和肿瘤。
在接受大手术后并发症风险增加的患者中,与深全身麻醉相比,浅全身麻醉并未降低 1 年死亡率。我们的试验定义了一个广泛的麻醉深度范围,在使用处理后的脑电图监测器滴定挥发性麻醉药浓度时,麻醉可以在此范围内安全进行。
新西兰健康研究理事会;澳大利亚国家卫生与医学研究理事会;香港研究资助局;英国国家卫生与保健研究院;美国国立卫生研究院。